Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PFKFB3 | Q16875 | 7/20 | 0.50 |
| ▸ | PFKFB4 | Q16877 | 6/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | CMA1 | P23946 | 4/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | BCL2 | P10415 | 1/20 | 0.36 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.36 |
| ▸ | EPM2A | O95278 | 1/20 | 0.35 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1742182 | 0.85 | PFKFB3 (0.51) | PFKFB3PFKFB4NPSR1L3MBTL1AKR1B1 | |
| SCHEMBL3946161 | 0.84 | PFKFB3 (0.53) | PFKFB3PFKFB4NPSR1L3MBTL1AKR1B1 | |
| SCHEMBL788031 | 0.83 | NPSR1 (0.52) | PFKFB3PFKFB4NPSR1L3MBTL1AKR1B1 | |
| SCHEMBL337593 | 0.82 | NPSR1 (0.62) | PFKFB3PFKFB4NPSR1L3MBTL1AKR1B1 | |
| SCHEMBL788282 | 0.81 | CMA1 (0.48) | PFKFB3PFKFB4NPSR1L3MBTL1AKR1B1 | |
| SCHEMBL787547 | 0.78 | L3MBTL1 (0.50) | PFKFB3PFKFB4NPSR1L3MBTL1AKR1B1 | |
| SCHEMBL788489 | 0.78 | PFKFB3 (0.54) | PFKFB3PFKFB4NPSR1L3MBTL1AKR1B1 | |
| SCHEMBL3684064 | 0.77 | NPSR1 (0.44) | PFKFB3PFKFB4NPSR1L3MBTL1AKR1B1 | |
| SCHEMBL787663 | 0.76 | HSD11B1 (0.43) | PFKFB3PFKFB4NPSR1L3MBTL1CMA1 | |
| SCHEMBL20549878 | 0.73 | EPM2A (0.43) | PFKFB3PFKFB4CA2EPM2APTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2616450-B1 | SULFONAMIDE COMPOUNDS | KANCERA AB (SE) | 2018-05-02 | — | — | EP | disclosed |
| EP-2616450-B1 | SULFONAMIDE COMPOUNDS | KANCERA AB (SE) | 2018-05-02 | — | — | EP | disclosed |
| EP-2188272-B1 | PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | REMYND NV (BE) | 2016-02-24 | — | — | EP | disclosed |
| US-9233946-B2 | Sulfonamide compounds | KANCERA AB (SE) | 2016-01-12 | — | — | US | disclosed |
| US-9233946-B2 | Sulfonamide compounds | KANCERA AB (SE) | 2016-01-12 | — | — | US | disclosed |
| US-9233946-B2 | Sulfonamide compounds | KANCERA AB (SE) | 2016-01-12 | — | — | US | disclosed |
| US-8722681-B2 | N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases | NV REMYND (BE) | 2014-05-13 | — | — | US | disclosed |
| US-8541406-B2 | Thiadiazole derivatives for the treatment of neurodegenerative diseases | NV REMYND (BE) | 2013-09-24 | — | — | US | disclosed |
| EP-2616450-A2 | SULFONAMIDE COMPOUNDS | Kancera AB (SE) | 2013-07-24 | — | — | EP | disclosed |
| US-20130172339-A1 | SULFONAMIDE COMPOUNDS | KANCERA AB (SE) | 2013-07-04 | — | — | US | disclosed |
| US-20090143448-A1 | NEW AMINOTHIAZOLES AS FBPASE INHIBITORS FOR DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-04 | — | — | US | disclosed |
| WO-2009068467-A1 | AMINOTHIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-04 | — | — | WO | disclosed |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-02-26 | — | — | US | disclosed |
| WO-2009019295-A2 | PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-02-12 | — | — | WO | disclosed |
| WO-2006134481-A1 | INHIBITORS OF 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE 1 | PFIZER INC. (US) | 2006-12-21 | — | — | WO | disclosed |
| EP-1696915-A1 | BENZENESULFONYLAMINO-PYRIDIN-2-YL DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11-BETA-HSD-1) FOR THE TREATMENT OF DIABETES AND OBESITY | Pfizer, Inc. (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20050148631-A1 | Amino heterocyclyl inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | AGOURON PHARMACEUTICALS, INC. | 2005-07-07 | — | — | US | disclosed |
| WO-2005060963-A1 | BENZENESULFONYLAMINO-PYRIDIN-2-YL DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11-BETA-HSD-1) FOR THE TREATMENT OF DIABETES AND OBESITY | PFIZER INC. (US) | 2005-07-07 | — | — | WO | disclosed |
| EP-1228066-A2 | SULFONAMIDE DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2002-08-07 | — | — | EP | disclosed |
| WO-2001032646-A2 | SULFONAMIDE DERIVATIVES | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148631-A1 | Amino heterocyclyl inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD17B11, HSD11B2 | PFKFB3 3931/4885PFKFB4 3867/4885NPSR1 1936/4885 |
| US-20130172339-A1 | SULFONAMIDE COMPOUNDS | SULT1A1, STS, ARSA | PFKFB3 952/4885PFKFB4 889/4885NPSR1 755/4885 |
| US-20090143448-A1 | NEW AMINOTHIAZOLES AS FBPASE INHIBITORS FOR DIABETES | FBP1, SLC5A1, DPP4 | PFKFB3 23/4885PFKFB4 31/4885NPSR1 2923/4885 |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | PFKFB3 4275/4885PFKFB4 4421/4885NPSR1 1776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.